A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range

NCT06041217 · Completed

Last updated 2026-05-28

This study is testing whether semaglutide helps reduce body weight in adults who are overweight or have obesity.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 242 people

Who can join Ages 18+ · all sexes

Timeline Started 2023-09 · est. completion 2025-05

Where 21 sites · China, Taiwan

What this study is testing ClinicalTrials.gov NCT06041217 ↗

Description as written by the study sponsor.

This study will look at how the investigational dose of semaglutide works in helping people with excess body weight, to lose weight. This study will compare the weight loss in people taking semaglutide to people taking "dummy" medicine (placebo). The study will last for about 1 year. The participants will have 12 visits at the clinic and 3 remote visits by phone calls with the study doctor or staff.

Treatments tested

Semaglutide Drug

Subcutaneous injections of semaglutide once-weekly at escalating doses every fourth week until maintenance dose of 2.4 mg of semaglutide is reached.
Placebo Drug

Subcutaneous injections of placebo once-weekly at escalation doses manner as semaglutide every fourth week until maintenance dose of placebo matched to 2.4 mg is reached.

Main thing measured	Change in Body Weight (%)
Sponsor	Novo Nordisk A/S
Conditions studied	Overweight, Obesity
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06041217 ↗